1Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction : a cohort study. Lancet, 2009,373 : 309 - 317.
2Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-or-function polymorghism and stent thrombosis percutaneous coronary intervention. Eur Heart I, 2009,30 : 916-922.
4Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med, 2003,3 : 147-162.
5Savi P, Herbert JM. Clopidogrel and ticlopidine : P2Y12 adeno- sine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost, 2005,31 : 174-183.
6Nasyuhana Sani Y, Sheau Chin L, Luen Hui L, et al. The CYP2C19 (*)1/(*)2 Genotype Does Not Adequately Predict Clopidogrel Respose in Healthy malaysian volunteers. Cardiol Res Pract, 2013,2013 : 128795.
7Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determi- nants of response to clopidogrel and cardiovascular events. N En- gl J Med, 2009,360 : 363-375.
8Ari H, Ozkan H, Karacinar A, et al. The effect of high-dose elopidogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol, 2012,157 : 370-384.
9Mega JL, Closee SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009,360 : 354-362.
